Saniona AB
OM:SANION
Denmark / Healthcare / Biotechnology
Exchange Data
Hide this widget
Price
6.14 SEK
Day change
-0.23 (-3.61%)
52-week range
1.74 - 9.91
7:30 PM - Closed
Summary of Saniona AB
Hide this widget
Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare dise...
Price History
Chart Gallery
Hide this widget
1 Week
1 Month
3 Months
1 Year
5 Years
10 Years
- (-)
Data Explorer
Hide this widget
Data could not be retrieved
Peer Benchmarks
Hide this widget
Quote
Value
Size
Growth
Profit
| SANION | Peers | Sector | |
|---|---|---|---|
Market Cap | 691 M | 110.1 M | 660.4 M |
Price % of 52 Week High | Premium | 55.8% | 62.6% |
Dividend Yield | 0.0% | 0.0% | 0.0% |
Shareholder Yield | Premium | -19.8% | -0.7% |
1 Year Price Total Return | 235.5% | -35.0% | -11.3% |
Beta (5 Year) | 0.77 | 0.76 | 0.64 |
In the News
Hide this widget
No data available
Fair Value
Hide this widget
Average
–
Upside
–
Uncertainty
–
Spread
–
Financial Health
Health Details
Hide this widget
Financial Health for Saniona AB is determined by ranking the company on over 100 factors against companies in the Healthcare sector and operating in Developed economic markets.
12345
Financial Models for Saniona AB
Model Gallery
Hide this widget
| DuPont ROE AnalysisView Updated 1 day ago |
| 10Y Historical FinancialsView Updated 1 day ago |
| 5Y Historical FinancialsView Updated 1 day ago |
| CAPM WACC ModelView Updated 18 hours ago |
| 10Y DCF EBITDA ExitView Updated 8 hours ago |
| 10Y DCF Revenue ExitView Updated 8 hours ago |
| 10Y DCF Growth ExitView Updated 8 hours ago |
| 5Y DCF EBITDA ExitView Updated 8 hours ago |
| 5Y DCF Revenue ExitView Updated 8 hours ago |
| 5Y DCF Growth ExitView Updated 8 hours ago |
| Earnings Power ValueView Updated 8 hours ago |
Historical Financials
Full Financials
Hide this widget
| (SEK in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Dec-22 | Dec-23 | Dec-24 | Dec-23 | Dec-24 |
| Income Statement | |||||
| Revenue | 15 | 17 | 335 | 5.37 | 313 |
| Operating Income | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Net Profit | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Diluted EPS | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| EBITDA | |||||
| Balance Sheet | |||||
| Cash & ST Invest. | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Current Assets | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Assets | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Current Liabilities | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Liabilities | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Equity | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Debt | 82 | 71 | 11 | 71 | 11 |
| Cash Flow Statement | |||||
| Cash Flow Operations | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Cash From Investing | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Cash From Financing | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Free Cash Flow | (283) | (86) | 249 | (20) | 293 |
Analyst Notes
March 26, 2025
Hide this widget